RINGSIDE: A Phase 2/3, Randomized, Multicenter Study toEvaluate AL102 in Patients with Progressing Desmoid Tumors


NCT Number:



Study Status:






You are being asked to participate in this study because you have been diagnosed with a progressive desmoid tumor. The purpose of this study is to see if the study drug, called AL102 (referred to from now on as the “study drug”), is safe and effective in people with progressive desmoid tumors. The study will also look at how your body responds to the study drug and how your body processes the drug . The study drug works by stopping a chemical pathway in the cells that allows desmoid tumors to grow. It is hoped that by stopping this pathway the study drug will stop desmoid tumor cells from growing and may cause them to shrink. The study drug is a capsule which is taken by mouth. Part A of the study is an ‘open-label’ study, which means both you and your study doctor will know that you are taking the study drug.

Are you Eligible? (Inclusion Criteria)

  • are you 18 years or older?
  • are you able to swallow whole capsules with no GI condition affecting absorption?
  • do you have a Histologically confirmed desmoid tumor by local pathologist?

Specialty Area(s)

Soft Tissue Sarcoma

Principal Investigator

Profile Headshot
  • Division Chief, Hematology/Oncology
  • Deputy Director, Herbert Irving Comprehensive Cancer Center

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032